New Drug Application submitted to FDA for plinabulin and G-CSF combination for prevention of chemotherapy-induced neutropenia (CIN)

Application for this selective immune-modulating microtubule-binding agent is supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone.

Source:

Biospace Inc.